MS drug natalizumab linked to liver injury per FDA
A recent report by the FDA links the multiple sclerosis drug natalizumab (Tysabri) to liver injury. It can occur as early as six days after the initial dose, per reports from the FDA.
The drug's marketers, Biogen Idec and Elan,issued a letter to clinicians, stating a warning about liver toxicity has been added to the natalizumab label.
The new warning informs the user that signs of liver injury "including markedly elevated serum hepatic enzymes and elevated total bilirubin" not only occurred within six days of initial doses, but also had "been reported for the first time after multiple doses."
One can only wonder how someone can feel safe taking this drug after reading such a warning. I applaud the manufacturer for at least including the warning on the label now, so that the consumer can be fully aware of risks and side effects of this drug.
Click here to read more from Medpage Today on this new warning for natalizumab or click here to read more on Tysabri.
